ZNF191 Inhibits Hepatocellular Carcinoma Metastasis via DLG1-mediated YAP1 Inactivation

Di Wu, Haitao Li, Yufeng Liu, Hexige Saiyin, Chenji Wang, Zhen Wei, Wenjiao Zen, Danyang Liu, Qi Chen, Haojie Huang, Guoyuan Liu, Songmin Jiang, Long YubioRxiv 2015 · DOI

TL;DR

This study identifies Zinc Finger Protein 191 (ZNF191) as a crucial suppressor of hepatocellular carcinoma (HCC) metastasis. ZNF191 inhibits cancer cell migration and spread by directly activating the expression of DLG1, a cell polarity protein that, in turn, inactivates the pro-metastatic YAP1 signaling pathway.

What Problem Does This Paper Address?

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths, with metastasis being a major contributor to poor patient outcomes. Identifying novel therapeutic targets and understanding the molecular mechanisms driving HCC metastasis are critical unmet needs. While previous research hinted at ZNF191's role in cancer, its specific function in HCC metastasis and the underlying pathways were unclear. This paper aims to elucidate ZNF191's role in HCC metastasis and uncover the molecular players involved.

Methods

The researchers employed a multi-pronged approach:

  • In vitro and in vivo experiments: They used HCC cell lines and animal models to assess the effects of ZNF191 manipulation (overexpression and knockdown) on cell migration, proliferation, and metastasis. Techniques included wound-healing assays, Transwell migration/invasion assays, and orthotopic tumor implantation in nude mice followed by in vivo imaging.
  • Molecular biology techniques: Western blotting and quantitative real-time PCR (qPCR) were used to measure protein and mRNA levels of key molecules.
  • Chromatin Immunoprecipitation-sequencing (ChIP-seq): This was a central technique to identify direct binding sites of ZNF191 on the genome, specifically to pinpoint its regulatory targets.
  • Immunohistochemistry (IHC): Used to assess the expression levels of ZNF191, DLG1, and YAP1 in human HCC tissue samples.
  • Luciferase reporter assays: To confirm the functional impact of ZNF191 binding on gene promoters.
  • Electrophoretic Mobility Shift Assay (EMSA): To verify direct binding of ZNF191 to DNA motifs.

Datasets

  • Human HCC tissue samples: A cohort of 120 HCC specimens was used for IHC analysis to correlate ZNF191, DLG1, and YAP1 expression with clinicopathological features. An additional 44 HCC samples were used for mRNA expression analysis.
  • Publicly available databases: TCGA (The Cancer Genome Atlas) database was utilized for analyzing ZNF191 and DLG1 mRNA expression levels in HCC specimens and their correlation with patient survival. Another database (http://www.cbioportal.org) was used for gene expression profiling.

Key Insights and Ideas

  • ZNF191 as a metastasis suppressor: Contrary to some previous findings suggesting a pro-proliferative role, this study strongly positions ZNF191 as a suppressor of HCC metastasis. This highlights the context-dependent nature of gene function in cancer.
  • DLG1 as a critical mediator: The discovery that ZNF191 directly targets the DLG1 promoter is a significant finding. DLG1, a known cell polarity protein, acts as the crucial link through which ZNF191 exerts its anti-metastatic effects.
  • YAP1 as the downstream effector: The study elegantly demonstrates that ZNF191's suppression of metastasis is mediated by the inactivation of YAP1 signaling, a pathway known to promote cell migration and invasion.
  • A novel ZNF191-DLG1-YAP1 axis: The identification of this specific signaling axis provides a new framework for understanding HCC metastasis and suggests potential therapeutic avenues.

Key Results

  • ZNF191 down-regulation in metastatic HCC: ZNF191 expression was significantly lower in metastatic HCC tissues compared to non-metastatic ones.
  • ZNF191 knockdown promotes migration and metastasis: Depleting ZNF191 in HCC cells led to increased cell motility in vitro and enhanced metastasis in vivo.
  • ZNF191 directly binds to the DLG1 promoter: ChIP-seq and EMSA confirmed that ZNF191 binds to specific TCAT repeating motifs in the DLG1 promoter, activating its transcription.
  • DLG1 knockdown rescues ZNF191's effect: When DLG1 was knocked down, the migration-promoting effects of ZNF191 depletion were abolished, indicating DLG1's essential role.
  • Inverse correlation between ZNF191/DLG1 and YAP1 activation: In HCC tissues, ZNF191 and DLG1 levels were positively correlated, while YAP1 activation (indicated by nuclear YAP1 staining) was inversely correlated with ZNF191 expression.

Limitations and Future Work

  • Upstream regulators of ZNF191: The study acknowledges that the regulators of ZNF191 expression remain elusive, suggesting future research into microRNA-940 and other transcriptional/post-translational mechanisms.
  • TAZ regulation: While YAP1 was used as a representative of the YAP/TAZ pathway, the study notes that ZNF191's influence on TAZ specifically requires further investigation.
  • Therapeutic challenges: Restoring ZNF191 expression while limiting its potential pro-proliferation effects presents a therapeutic challenge that warrants further exploration.
  • Discrepancy in DLG1 correlation: The study notes a discrepancy where DLG1-negative cases were correlated with high serum AFP and larger tumor size, suggesting the existence of other mediators upstream of YAP1 and downstream of ZNF191.

Summary updated

Abstract

Abstract Searching targets for hepatocellular carcinoma (HCC) treatment, we identified zinc finger protein 191 (ZNF191) as a suppressor against HCC metastasis. Over-expressing ZNF191 in HCC cells impaired cell motility, while ZNF191 depletion promoted HCC cell migration in vitro and metastasis in vivo through triggering yes-associated protein 1 (YAP1) signaling. Chromatin immunoprecipitation-sequencing (ChIP-seq) revealed that ZNF191 specifically bound to the promoter of Discs, Large homolog 1 ( DLG1 ), a cell polarity maintainer and a negative regulator of YAP1. Double-knockdown experiments showed that DLG1 was not only the mediator of ZNF191’s function to suppress migration but also a link between ZNF191 and YAP1 signaling. ZNF191 was down-regulated in metastatic HCCs, correlating positively with DLG1 levels and inversely with YAP1 activation. Our findings indicate ZNF191 functions as a metastasis suppressor via DLG1-mediated YAP1 signaling inactivation.
BibTeX
@misc{wu2015znf,
  author = {Di Wu and Haitao Li and Yufeng Liu and Hexige Saiyin and Chenji Wang and Zhen Wei and Wenjiao Zen and Danyang Liu and Qi Chen and Haojie Huang and Guoyuan Liu and Songmin Jiang and Long Yu},
  title = {{ZNF191 Inhibits Hepatocellular Carcinoma Metastasis via DLG1-mediated YAP1 Inactivation}},
  year = {2015},
  doi = {10.1101/027060},
  howpublished = {bioRxiv},
}
Figure